

## PHARMACY POLICY – 5.01.545


## Cialis® (tadalafil) for Benign Prostatic Hyperplasia

Effective Date: Dec. 1, 2018  
Last Revised: Nov. 21, 2018  
Replaces: N/A

RELATED MEDICAL POLICIES:  
5.01.522 Advanced Therapies for Pharmacological Treatment of Pulmonary Arterial Hypertension

Select a hyperlink below to be directed to that section.

[POLICY CRITERIA](#) | [CODING](#) | [RELATED INFORMATION](#)  
[EVIDENCE REVIEW](#) | [REFERENCES](#) | [HISTORY](#)

 Clicking this icon returns you to the hyperlinks menu above.

---

## Introduction

Benign prostatic hyperplasia (BPH) is the medical term for an enlarged prostate. BPH is a noncancerous condition caused by prostate cells that keep multiplying. Over time, the excess prostate tissue puts pressure on the tube that carries urine and semen out of the body. As more pressure is applied, urinary difficulties often develop. These can include a weak or slow stream, a sense that the bladder isn't completely empty, and/or needing to urinate frequently and urgently. Cialis® was originally developed to treat erectile dysfunction (difficulty in achieving and keeping an erection). However, it was discovered that Cialis also addresses symptoms of BPH. This policy describes when Cialis may be approved for BPH. Using Cialis for erectile dysfunction is not covered.

**Note:** The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

## Policy Coverage Criteria

---

Documentation in the form of chart notes/medical records must be provided with prior authorization review for the agents described below.

Indication	Medical Necessity
<p><b>Treatment for symptoms of benign prostatic hyperplasia (BPH)</b></p>	<p><b>Cialis® (tadalafil) may be considered medically necessary as second line treatment for symptoms of benign prostatic hyperplasia (BPH).</b></p> <p><b>Cialis® (tadalafil) may be considered medically necessary when ALL of the following conditions are met:</b></p> <ul style="list-style-type: none"> <li>• Patient has a diagnosis of benign prostatic hyperplasia (BPH)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Patient has previously failed, had inadequate response to or failed to tolerate a generic alpha blocker (terazosin, tamsulosin, doxazosin, or alfuzosin)</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>• Patient has previously failed, had inadequate response to or failed to tolerate, Proscar® (finasteride), Avodart® (dutasteride), or Rapaflo® (silodosin)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Prescription is for either 2.5mg or 5mg taken once daily.</li> </ul> <p><b>Note:</b> Cialis (tadalafil) is also available in 10mg and 20mg tablets for use as needed. These are indicated ONLY for treatment of erectile dysfunction, not BPH.</p>

Indication	Contract Exclusion
<p><b>Erectile dysfunction in patients without BPH</b></p>	<p><b>All other uses of Cialis® (tadalafil) for conditions not outlined in this policy are considered investigational.</b></p>

Indication	Investigational
<p><b>All other indications</b></p>	<p><b>Use of Cialis® (tadalafil) for all other indications is considered investigational.</b></p>



**Note:** Tadalafil is available as Adcirca® in different strengths for the treatment of pulmonary arterial hypertension (PAH). For these patients, refer to the pulmonary arterial hypertension guidelines contained in a separate medical policy (see [Related Policies](#)).

## Coding

---

N/A

## Related Information

---

### Benefit Application

This policy applies to all lines of business. Language pertaining specifically to contractual exclusion of tadalafil is applicable only to benefits that exclude coverage for treatment of erectile dysfunction.

This policy is managed through the Pharmacy benefit.

## Evidence Review

---

### Description

Benign prostatic hyperplasia (BPH) is a condition characterized by epithelial and stromal cell proliferation (enlargement) of the prostate gland. BPH and BPH-related lower urinary tract symptoms (LUTS) are age-dependent, with BPH being one of the top 10 most commonly diagnosed conditions in men over 50 years of age. The estimated prevalence of LUTS secondary to BPH in Caucasian Americans between the ages of 50 and 79 in 2000 was 42%. In a European cross sectional study of men >40 years of age attending urology clinics, the prevalence of LUTS secondary to BPH was 56% and erectile dysfunction was 40%. These conditions are also frequently comorbid in the same men. In BPH, as the prostate gland enlarges it may constrict the urethra and/or the bladder wall may thicken and become irritable resulting in lower urinary



tract symptoms such as diminished urine stream, intermittency, straining, polyuria, nocturia, urinary urgency, and inability to empty the bladder.

Three classes of drugs are currently recommended by the AUA for the treatment of BPH: alpha adrenergic antagonists, 5-alpha reductase inhibitors, and anticholinergics. The approval of tadalafil for BPH occurred after the latest AUA management update; consequently its use for BPH is not addressed. The mechanism of action of alpha adrenergic antagonists is blockade of alpha-1 receptors in the prostate, bladder, and urethra which relaxes smooth muscle in these tissues and improves urine flow and symptoms associated with BPH. It is important to note that drugs in this class do not reduce prostate size. 5-Alpha reductase inhibitors interfere with testosterone's stimulatory effect on prostate enlargement and therefore do reduce prostate size.

Alpha-1 adrenergic antagonists are generally considered a preferred first-line treatment option for patients with moderate to severe LUTS secondary to BPH. However, prazosin and phenoxybenzamine are not recommended due to a lack of evidence of effectiveness. Use of 5-alpha reductase inhibitors is recommended for patients with moderate to severe LUTS and demonstrated increased prostatic volume, prostate specific antigen (as a proxy for volume), and/or prostatic enlargement on digital rectal exam. These agents are not recommended for the treatment of LUTS in men without prostatic enlargement. Combination therapy with an alpha adrenergic antagonist and a 5-alpha reductase inhibitor has been shown to provide greater symptom relief and reduction in disease progression (prostate enlargement) compared with an agent from either class alone.

## Rationale

The clinical efficacy of tadalafil 5 mg once daily for lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) was primarily established in 3 similarly designed multinational, 12-week, randomized, double-blind, placebo-controlled trials. Two of these studies were conducted in men with LUTS suggestive of BPH (Porst, 2011 and Roehrborn, 2008) and one was specific to men with comorbid BPH and erectile dysfunction (Egerdie, 2011). The primary efficacy endpoint in all 3 trials was change from baseline in total International Prostate Symptom Score (IPSS). The IPSS assesses severity of the spectrum of symptoms associated with BPH. The comorbid ED study had a co-primary endpoint that was change from baseline in the erectile function domain score of International Index of Erectile Function (IIEF-EF). All 3 trials consistently showed a statistically and clinically significant improvement in these surrogate outcomes after 12-weeks. While these studies were not specifically designed to evaluate the following endpoints, nocturia and objective urodynamic measures (peak urinary flow and postvoid residual volume) were consistently not improved.



A 1-year, open-label, safety extension of the registrational Roehrborn (2008) study suggests efficacy for LUTS secondary to BPH is maintained longer-term (Donatucci, 2011). Two other preliminary RCTs also consistently support the short-term (12-week) efficacy of tadalafil 5 mg once daily for LUTS secondary to BPH with or without comorbid ED.

Results from one unpublished, multinational, 12-week, randomized, double-blind, double dummy, placebo-controlled trial with a parallel tamsulosin (FLOMAX) 0.4 mg once daily arm were recently posted on clinicaltrials.gov (NCT00970632). While this study was not designed to compare the two active drugs, tadalafil 5 mg once daily appeared to provide similar improvements to that of tamsulosin (FLOMAX) 8 in men with LUTS suggestive of BPH. As might be expected, tadalafil appeared superior to the alpha-blocker for treatment of comorbid erectile dysfunction.

One prospective, open-label, uncontrolled study was identified on literature search that examined the efficacy and safety of add-on tadalafil at the approved 5 mg daily dose combined with an alpha-blocker (tamsulosin [FLOMAX] 0.2 mg or alfuzosin [UROXATRAL] 10 mg) for 12-weeks in 158 Korean men with concurrent LUTS-BPH and ED. Total IPSS and IIEF-5 were significantly ( $p < 0.001$ ) improved with combination therapy, but Qmax and PVR did not, compared to baseline low-dose alpha-blocker monotherapy.

The registrational RCTs show tadalafil 5 mg once daily to be well tolerated for the short-term treatment of LUTS suggestive of BPH with or without comorbid ED. Overall, adverse events were infrequent and the majority (>95%) were mild to moderate in severity. No unexpected adverse events occurred. No clinically significant changes in vitals or electrocardiogram were observed. Rates of myocardial infarction appeared similar to that of placebo in the same population, with the caveat that these trials were of short duration (12 weeks). In short-term (12-week) clinical trials, incidence of a positive orthostatic test was similar in tadalafil-treated and placebo-treated LUTS-BPH patients, about 20%. No priapism was reported.

A long-term (1-year) safety extension in the target population found no new or greater frequency of any adverse events, serious adverse events, or discontinuation for adverse events compared to double-blind short-term (12-week) treatment (Donatucci, 2011).

Two open-label safety extension trials of tadalafil 5 mg once daily in men with ED also showed the drug to be well tolerated for up to 2 years. No unexpected adverse events were observed. No deaths or serious adverse events, cardiovascular or otherwise, were attributed to study drug.

No sudden hearing or vision losses (non-arteritic anterior ischemic optic neuropathy [NAION]) were reported in short- or long-term clinical trials for LUTS secondary to BPH.



In the unpublished, multinational, 12-week, randomized, double-blind, double dummy, placebo-controlled trial with the parallel tamsulosin 0.4 mg once daily arm (NCT00970632), incidence of adverse events, serious adverse events, and discontinuation for adverse events appeared similar between tadalafil (CIALIS) 5 mg, tamsulosin (FLOMAX) 0.4 mg, and placebo once daily in men with LUTS-BPH with or without ED.

A prospective, multicenter, randomized, open-label, parallel-group study (Yoshida et al. 2017) compared the efficacy and safety of silodosin versus tadalafil in 192 patients with LUTS-BPH. The primary efficacy endpoint was change in IPSS total symptom score before and after Period 1 treatment (Week 4). Both silodosin and tadalafil demonstrated statistically significant improvement from baseline (Week 0) IPSS total symptom score, with a mean  $\pm$  SD change of  $-10.1 \pm 6.4$  ( $P < 0.0001$ ) and  $-8.0 \pm 6.3$  ( $< 0.0001$ ), respectively. The difference between silodosin and tadalafil was statistically significant ( $P = 0.0277$ ). In addition, silodosin demonstrated a significantly greater decrease in symptoms of incomplete emptying, weak stream, and nocturia than tadalafil ( $P = 0.0254$ ,  $P = 0.0067$ , and  $P = 0.0387$ ). Adverse drug reactions occurred more frequently with silodosin (23.4%) than tadalafil (8.4%), but no serious adverse reactions were observed in both arms. Nervous system disorders (i.e., dizziness and headache) and gastrointestinal disorders (i.e. soft feces) were reported in both arms, but orthostatic hypotension ( $n = 2$ ), nasal congestion ( $n = 4$ ), ejaculation disorder ( $n = 6$ ), and retrograde ejaculation ( $n = 5$ ) were only reported in the silodosin arm.

### ***2014 Update***

Updated per literature search 7/1/13 to 10/31/14. No changes required.

### ***2015 Update***

Updated per literature search 11/1/14 to 9/15/15. There was no information which prompted a change in the policy statements. Rapaflo was added as a qualifier to coverage of Cialis along with Proscar and Avodart. Verbiage also updated to call them out separately from the generic alpha blockers.



## *2016 Update*

A literature search was conducted between 04/01/15 and 12/06/16. No information was found which would prompt a change in the existing policy statements.

## *2017 Update*

A literature search was conducted between 07/01/16 and 11/01/17. No information was found which would prompt a change in the existing policy statements.

## *2018 Update*

A literature search was conducted between 11/01/17 and 10/31/18. No information was found which would prompt a change in the existing policy statements. Tadalafil was studied in a placebo-controlled phase 3 RCT in patients 7-14 years of age with Duchenne Muscular Dystrophy. Tadalafil failed to show benefit in reducing rate of ambulatory decline.

## References

---

1. Porst H, McVary KT, Montorsi F, et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. *Eur Urol* 2009;56(4):727-735.
2. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Urol* 2007;177:1401-1407.
3. Lee JY, Park SY, Jeong TY, et al. Combined tadalafil and  $\alpha$ -blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter prospective study. *J Andrology* 2012 Aug 25 [epub ahead of print].
4. Porst H, Rajfer J, Casabe A, et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. *J Sex Med* 2008;5:2160-2169.
5. Porst H, Kim ED, Casabe AR, et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. *Eur Urol* 2011;60(5):1105-1113.
6. Roehrborn CG, McVary KT, Elion-Mboussa A, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. *J Urol* 2008;180:1228-1234.
7. Donatucci CF, Brock GB, Goldfischer ER, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. *BJUI* 2011;107:1110-1116.



8. Roehrborn CG, Kaminetsky JC, Auerbach SM, et al. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil administration. *BJUI* 2009;105:502-507.
9. Broderick GA, Brock GB, Roehrborn CG, et al. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. *Urology* 2010;75:1452-1459.
10. Egerdie RB, Auerbach S, Roehrborn CG, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. *J Sex Med* 2011 Oct 7 [epub ahead of print].
11. National Kidney and Urological Diseases Information Clearinghouse. Prostate enlargement: benign prostatic hyperplasia. Available at <http://kidney.niddk.nih.gov/kudiseases/pubs/prostateenlargement> Accessed November 2018.
12. National Kidney and Urological Diseases Information Clearinghouse. Kidney and urologic diseases statistics for the United States. Available at <http://kidney.niddk.nih.gov/kudiseases/pubs/kustats> Accessed November 2018.
13. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003/updated 2010). Available at <http://www.auanet.org/education/guidelines/benign-prostatic-hyperplasia.cfm> 2013 Accessed November 2018.
14. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. *N Engl J Med*. 2003;349:2387-2398.
15. Yoshida M, Origasa H. and Seki N. Comparison of silodosin versus tadalafil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. *LUTS*. 2017; 9: 176–186.
16. Victor RG, Sweeney HL, Finkel R, et al. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. *Neurology*. 2017 Oct 24;89(17):1811-1820. doi: 10.1212/WNL.0000000000004570. Epub 2017 Sep 29.

## History

Date	Comments
08/12/13	New policy. Add to Prescription Drug section.
12/17/14	Annual Review. Policy updated with literature review. No change in policy statements.
10/13/15	Annual Review. Added Rapaflo as a qualifier to coverage of Cialis along with Proscar and Avodart. Verbiage also updated to call them out separately from the generic alpha blockers. Policy statements unchanged.
01/01/17	Annual Review, approved December 13, 2016. No changes to Policy Criteria.
12/01/17	Annual Review, approved November 21, 2017. No changes to the Policy Criteria. One study was added to the Reference List.
07/01/18	Interim Review, approved June 5, 2018. Added requirement of documentation in the form of chart notes/medical records for medical necessity review of medications within this policy.
12/01/18	Annual Review, approved November 21, 2018. No changes. Added reference to a failed trial in patients with DMD.





**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2018 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.



**Discrimination is Against the Law**

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:

- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:

Civil Rights Coordinator - Complaints and Appeals  
PO Box 91102, Seattle, WA 98111  
Toll free 855-332-4535, Fax 425-918-5592, TTY 800-842-5357  
Email AppealsDepartmentInquiries@Premera.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: U.S. Department of Health and Human Services  
200 Independence Avenue SW, Room 509F, HHH Building  
Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)  
Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

**Getting Help in Other Languages**

**This Notice has Important Information.** This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call 800-722-1471 (TTY: 800-842-5357).

**አማርኛ (Amharic):**

ይህ ማስታወቂያ አስፈላጊ መረጃ ይዟል። ይህ ማስታወቂያ ስለ ማመልከቻዎ ወይም የ Premera Blue Cross ሽፋን አስፈላጊ መረጃ ሊኖረው ይችላል። በዚህ ማስታወቂያ ውስጥ ቁልፍ ቀናት ሊኖሩ ይችላሉ። የጤና ሽፋንዎን ለመጠበቅና በአስፈላጊ እርዳታ ለማግኘት በተውሰኑ የጊዜ ገደቦች እርምጃ መውሰድ ይገባዎት ይሆናል። ይህን መረጃ እንዲያገኙ እና የለምንም ክፍያ በቋንቋዎ እርዳታ እንዲያገኙ መሰታወቅ አለዎት። በስልክ ቁጥር 800-722-1471 (TTY: 800-842-5357) ይደውሉ።

**العربية (Arabic):**

يحتوي هذا الإشعار على معلومات هامة. قد يحتوي هذا الإشعار على معلومات مهمة بخصوص طلبك أو التخطيط التي تزيد الحصول عليها من خلال Premera Blue Cross. قد تكون هناك تواريخ مهمة في هذا الإشعار. وقد تحتاج لاتخاذ إجراء في تاريخ معينة للحفاظ على تغطيتك الصحية أو المساعدة في دفع التكاليف. يحق لك الحصول على هذه المعلومات والمساعدة بلغتك دون تكبد أية تكلفة. اتصل بـ 800-722-1471 (TTY: 800-842-5357)

**中文 (Chinese):**

**本通知有重要的訊息。**本通知可能有關於您透過 Premera Blue Cross 提交的申請或保險的重要訊息。本通知內可能有重要日期。您可能需要在截止日期之前採取行動，以保留您的健康保險或者費用補貼。您有權利免費以您的母語得到本訊息和幫助。請撥電話 800-722-1471 (TTY: 800-842-5357)。

**Oromoo (Cushite):**

**Beeksisni kun odeeffannoo barbaachisaa qaba.** Beeksisni kun sagantaa yookan karaa Premera Blue Cross tiin tajaajila keessan ilaalchisee odeeffannoo barbaachisaa qabaachuu danda'a. Guyyaawwan murteessaa ta'an beeksisa kana keessatti ilaalaa. Tarii kaffaltiidhaan deeggaramuuf yookan tajaajila fayyaa keessaniif guyyaa dhumaa irratti wanti raawwattan jiraachuu danda'a. Kaffaltii irraa bilisa haala ta'een afaan keessaniin odeeffannoo argachuu fi deeggarsa argachuuf mirga ni qabaattu. Lakkoofsa bilbilaa 800-722-1471 (TTY: 800-842-5357) tii bilbilaa.

**Français (French):**

**Cet avis a d'importantes informations.** Cet avis peut avoir d'importantes informations sur votre demande ou la couverture par l'intermédiaire de Premera Blue Cross. Le présent avis peut contenir des dates clés. Vous devez peut-être prendre des mesures par certains délais pour maintenir votre couverture de santé ou d'aide avec les coûts. Vous avez le droit d'obtenir cette information et de l'aide dans votre langue à aucun coût. Appelez le 800-722-1471 (TTY: 800-842-5357).

**Kreyòl ayisyen (Creole):**

**Avi sila a gen Enfòmasyon Enpòtan ladann.** Avi sila a kapab genyen enfòmasyon enpòtan konsènan aplikasyon w lan oswa konsènan kouvèti asirans lan atravè Premera Blue Cross. Kapab genyen dat ki enpòtan nan avi sila a. Ou ka gen pou pran kèk aksyon avan sèten dat limit pou ka kenbe kouvèti asirans sante w la oswa pou yo ka ede w avèk depans yo. Se dwa w pou resewva enfòmasyon sa a ak asistans nan lang ou pale a, san ou pa gen pou peye pou sa. Rele nan 800-722-1471 (TTY: 800-842-5357).

**Deutsche (German):**

**Diese Benachrichtigung enthält wichtige Informationen.** Diese Benachrichtigung enthält unter Umständen wichtige Informationen bezüglich Ihres Antrags auf Krankenversicherungsschutz durch Premera Blue Cross. Suchen Sie nach eventuellen wichtigen Terminen in dieser Benachrichtigung. Sie könnten bis zu bestimmten Stichtagen handeln müssen, um Ihren Krankenversicherungsschutz oder Hilfe mit den Kosten zu behalten. Sie haben das Recht, kostenlose Hilfe und Informationen in Ihrer Sprache zu erhalten. Rufen Sie an unter 800-722-1471 (TTY: 800-842-5357).

**Hmoob (Hmong):**

**Tsab ntawv tshaj xo no muaj cov ntshiab lus tseem ceeb.** Tej zaum tsab ntawv tshaj xo no muaj cov ntshiab lus tseem ceeb txog koj daim ntawv thov kev pab los yog koj qhov kev pab cuam hnu ntawm Premera Blue Cross. Tej zaum muaj cov hnu tseem ceeb uas sau rau hauv daim ntawv no. Tej zaum koj kuj yuav tau ua qee yam uas pab kom koj ua tsis pub dhau cov caij nyuog uas teev tseg rau hauv daim ntawv no mas koj thiaj yuav tau txais kev pab cuam kho mob los yog kev pab them tej nqi kho mob ntawd. Koj muaj cai kom lawv muab cov ntshiab lus no uas tau muab sau ua koj hom lus pub dawb rau koj. Hu rau 800-722-1471 (TTY: 800-842-5357).

**Iloko (Ilocano):**

**Daytoy a Pakdaar ket naglaon iti Napateg nga Impormasion.** Daytoy a pakdaar mabalin nga adda ket naglaon iti napateg nga impormasion maipanggep iti aplikasyonyo wenna coverage babaen iti Premera Blue Cross. Daytoy ket mabalin dagiti importante a petsa iti daytoy a pakdaar. Mabalin nga adda rumbeng nga aramidenyo nga addang sakbay dagiti partikular a naituding nga aldaw tapno mapagtalinaedyo ti coverage ti salun-atyto wenna tulong kadagiti gastos. Adda karbenganyo a mangala iti daytoy nga impormasion ken tulong iti bukodyo a pagsasao nga awan ti bayadanyo. Tumawag iti numero nga 800-722-1471 (TTY: 800-842-5357).

**Italiano (Italian):**

**Questo avviso contiene informazioni importanti.** Questo avviso può contenere informazioni importanti sulla tua domanda o copertura attraverso Premera Blue Cross. Potrebbero esserci date chiave in questo avviso. Potrebbe essere necessario un tuo intervento entro una scadenza determinata per consentirti di mantenere la tua copertura o sovvenzione. Hai il diritto di ottenere queste informazioni e assistenza nella tua lingua gratuitamente. Chiama 800-722-1471 (TTY: 800-842-5357).

**日本語 (Japanese):**

この通知には重要な情報が含まれています。この通知には、Premera Blue Cross の申請または補償範囲に関する重要な情報が含まれている場合があります。この通知に記載されている可能性がある重要な日付をご確認ください。健康保険や有料サポートを維持するには、特定の期日までに行動を取らなければならない場合があります。ご希望の言語による情報とサポートが無料で提供されます。800-722-1471 (TTY: 800-842-5357)までお電話ください。

**한국어 (Korean):**

본 통지서에는 중요한 정보가 들어 있습니다. 즉 이 통지서는 귀하의 신청에 관하여 그리고 Premera Blue Cross 를 통한 커버리지에 관한 정보를 포함하고 있을 수 있습니다. 본 통지서에는 핵심이 되는 날짜들이 있을 수 있습니다. 귀하의 건강 커버리지를 계속 유지하거나 비용을 절감하기 위해서 일정한 마감일까지 조치를 취해야 할 필요가 있을 수 있습니다. 귀하의 이러한 정보와 도움을 귀하의 언어로 비용 부담없이 얻을 수 있는 권리가 있습니다. 800-722-1471 (TTY: 800-842-5357) 로 전화하십시오.

**ລາວ (Lao):**

ແຈ້ງການນີ້ມີຂໍ້ມູນສໍາຄັນ. ແຈ້ງການນີ້ອາດຈະມີຂໍ້ມູນສໍາຄັນກ່ຽວກັບຄໍາຮ້ອງສະໝັກ ຫຼື ຄວາມຄົມຄອງປະກັນໄພຂອງທ່ານຜ່ານ Premera Blue Cross. ອາດຈະມີວັນທີ່ສໍາຄັນໃນແຈ້ງການນີ້. ທ່ານອາດຈະຈໍາເປັນຕ້ອງດໍາເນີນການຕາມກຳນົດ ເວລາສະເພາະເພື່ອຮັກສາຄວາມຄົມຄອງປະກັນສະພາບ ຫຼື ຄວາມຊ່ວຍເຫຼືອເວັ້ນເວີ້ ຄ່າໃຊ້ຈ່າຍຂອງທ່ານໄດ້. ທ່ານມີສິດໄດ້ຮັບຂໍ້ມູນນີ້ ແລະ ຄວາມຊ່ວຍເຫຼືອເປັນພາສາຂອງທ່ານໂດຍບໍ່ເສຍຄ່າ. ໃຫ້ໃບທາ 800-722-1471 (TTY: 800-842-5357).

**ភាសាខ្មែរ (Khmer):**

សេចក្តីជូនដំណឹងនេះមានព័ត៌មានយ៉ាងសំខាន់។ សេចក្តីជូនដំណឹងនេះប្រហែលជាមានព័ត៌មានយ៉ាងសំខាន់អំពីទម្រង់បែបបទ ឬការរៀបចំរបស់អ្នកកាមរយ: Premera Blue Cross ។ ប្រហែលជាមាន កាលបរិច្ឆេទសំខាន់នៅក្នុងសេចក្តីជូនដំណឹងនេះ។ អ្នកប្រហែលជាត្រូវការបញ្ជាក់សមត្ថភាព ដល់កំណត់ថ្លៃជាតំបន់នានា ដើម្បីនឹងរក្សាទុកការធានារ៉ាប់រងអន្តរជាតិរបស់អ្នក ឬប្រាក់ដុល្លារចេញថ្លៃ។ អ្នកមានសិទ្ធិទទួលបានព័ត៌មាននេះ និងដុល្លារនៅក្នុងភាសារបស់អ្នកដោយមិនអស់លុយឡើយ។ សូមទូរស័ព្ទ 800-722-1471 (TTY: 800-842-5357)។

**ਪੰਜਾਬੀ (Punjabi):**

ਇਸ ਨੋਟਿਸ ਵਿਚ ਖਾਸ ਜਾਣਕਾਰੀ ਹੈ. ਇਸ ਨੋਟਿਸ ਵਿਚ Premera Blue Cross ਵਲੋਂ ਤੁਹਾਡੀ ਕਵਰੇਜ ਅਤੇ ਅਰਜੀ ਬਾਰੇ ਮਹੱਤਵਪੂਰਨ ਜਾਣਕਾਰੀ ਹੋ ਸਕਦੀ ਹੈ . ਇਸ ਨੋਟਿਸ ਨਵ ਖਾਸ ਤਾਰੀਖਾਂ ਹੋ ਸਕਦੀਆਂ ਹਨ. ਜੇਕਰ ਤੁਸੀਂ ਜਸਰਤ ਕਵਰੇਜ ਰਿੱਖਣੀ ਹੋਵੇ ਜਾਂ ਓਸ ਦੀ ਲਾਗਤ ਜਵਿੱਚ ਮਦਦ ਦੇ ਇਕੱਠ ਹੋ ਤਾਂ ਤੁਹਾਨੂੰ ਅੰਤਮ ਤਾਰੀਖ ਤੋਂ ਪਹਿਲਾਂ ਢੁੱਝ ਖਾਸ ਕਦਮ ਚੁੱਕਣ ਦੀ ਲੋੜ ਹੋ ਸਕਦੀ ਹੈ ,ਤੁਹਾਨੂੰ ਮੁਫਤ ਵਿੱਚ ਤੋਂ ਅਪਣੀ ਭਾਸ਼ਾ ਵਿੱਚ ਜਾਣਕਾਰੀ ਅਤੇ ਮਦਦ ਪ੍ਰਾਪਤ ਕਰਨ ਦਾ ਅਧਿਕਾਰ ਹੈ ,ਕਾਲ 800-722-1471 (TTY: 800-842-5357).

**فارسی (Farsi):**

این اعلامیه حاوی اطلاعات مهم میباشد. این اعلامیه ممکن است حاوی اطلاعات مهم درباره فرم تقاضا و یا پوشش بیمه ای شما از طریق Premera Blue Cross باشد. به تاریخ های مهم در این اعلامیه توجه نمایید. شما ممکن است برای حفظ پوشش بیمه تان یا کمک در پرداخت هزینه های درمانی تان، به تاریخ های مشخصی برای انجام کارهای خاصی احتیاج داشته باشید. شما حق این را دارید که این اطلاعات و کمک را به زبان خود به طور رایگان دریافت نمایید. برای کسب اطلاعات با شماره 800-722-1471 (کلیر بران TTY تماس باشماره 800-842-5357) تماس برقرار نمایید.

**Polskie (Polish):**

To ogłoszenie może zawierać ważne informacje. To ogłoszenie może zawierać ważne informacje odnośnie Państwa wniosku lub zakresu świadczeń poprzez Premera Blue Cross. Prosimy zwrócić uwagę na kluczowe daty, które mogą być zawarte w tym ogłoszeniu aby nie przekroczyć terminów w przypadku utrzymania polisy ubezpieczeniowej lub pomocy związanej z kosztami. Macie Państwo prawo do bezpłatnej informacji we własnym języku. Zadzwońcie pod 800-722-1471 (TTY: 800-842-5357).

**Português (Portuguese):**

Este aviso contém informações importantes. Este aviso poderá conter informações importantes a respeito de sua aplicação ou cobertura por meio do Premera Blue Cross. Poderão existir datas importantes neste aviso. Talvez seja necessário que você tome providências dentro de determinados prazos para manter sua cobertura de saúde ou ajuda de custos. Você tem o direito de obter esta informação e ajuda em seu idioma e sem custos. Ligue para 800-722-1471 (TTY: 800-842-5357).

**Română (Romanian):**

Prezenta notificare conține informații importante. Această notificare poate conține informații importante privind cererea sau acoperirea asigurării dumneavoastră de sănătate prin Premera Blue Cross. Pot exista date cheie în această notificare. Este posibil să fie nevoie să acționați până la anumite termene limită pentru a vă menține acoperirea asigurării de sănătate sau asistența provizorie la costuri. Aveți dreptul de a obține gratuit aceste informații și ajutor în limba dumneavoastră. Sunați la 800-722-1471 (TTY: 800-842-5357).

**Русский (Russian):**

Настоящее уведомление содержит важную информацию. Это уведомление может содержать важную информацию о вашем заявлении или страховом покрытии через Premera Blue Cross. В настоящем уведомлении могут быть указаны ключевые даты. Вам, возможно, потребуется принять меры к определенным предельным срокам для сохранения страхового покрытия или помощи с расходами. Вы имеете право на бесплатное получение этой информации и помощь на вашем языке. Звоните по телефону 800-722-1471 (TTY: 800-842-5357).

**Fa'asamoa (Samoan):**

Atonu ua iai i lenei fa'asilasilaga ni fa'amatalaga e sili ona taua e tatau ona e malamalama i ai. O lenei fa'asilasilaga o se fesoasoani e fa'amatala atili i ai i le tulaga o le polokalame, Premera Blue Cross, ua e tau fia maua atu i ai. Fa'amolemole, ia e iloilo fa'alelei i aso fa'apitoa olo'o iai i lenei fa'asilasilaga taua. Masalo o le'a iai ni feau e tatau ona e faia ao le'i aulia le aso ua ta'ua i lenei fa'asilasilaga ina ia e iai pea ma maua fesoasoani mai ai i le polokalame a le Malo olo'o e iai i ai. Olo'o iai iate oe le aia tatau e maua atu i lenei fa'asilasilaga ma lenei fa'matalaga i legagana e te malamalama i ai aunoa ma se togiga tupe. Vili atu i le telefoni 800-722-1471 (TTY: 800-842-5357).

**Español (Spanish):**

Este Aviso contiene información importante. Es posible que este aviso contenga información importante acerca de su solicitud o cobertura a través de Premera Blue Cross. Es posible que haya fechas clave en este aviso. Es posible que deba tomar alguna medida antes de determinadas fechas para mantener su cobertura médica o ayuda con los costos. Usted tiene derecho a recibir esta información y ayuda en su idioma sin costo alguno. Llame al 800-722-1471 (TTY: 800-842-5357).

**Tagalog (Tagalog):**

Ang Paunawa na ito ay naglalaman ng mahalagang impormasyon tungkol sa iyong aplikasyon o pagsakop sa pamamagitan ng Premera Blue Cross. Maaaring may mga mahalagang petsa dito sa paunawa. Maaring mangailangan ka na magsagawa ng hakbang sa ilang mga itinakdang panahon upang mapanatili ang iyong pagsakop sa kalusugan o tulong na walang gastos. May karapatan ka na makakuha ng ganiitong impormasyon at tulong sa iyong wika ng walang gastos. Tumawag sa 800-722-1471 (TTY: 800-842-5357).

**ไทย (Thai):**

ประกาศนี้มีข้อมูลสำคัญ ประกาศนี้อาจมีข้อมูลที่สำคัญเกี่ยวกับกาการสมัครหรือขอบเขตประกันสุขภาพของคุณผ่าน Premera Blue Cross และอาจมีกำหนดการในประกาศนี้ คุณอาจจะต้องดำเนินการภายในกำหนดระยะเวลาที่แน่นอนเพื่อจะรักษาการประกันสุขภาพของคุณหรือการช่วยเหลือที่มีค่าใช้จ่าย คุณมีสิทธิที่จะได้รับข้อมูลและความช่วยเหลือนี้ในภาษาของคุณโดยไม่มีค่าใช้จ่าย โทร 800-722-1471 (TTY: 800-842-5357)

**Український (Ukrainian):**

Це повідомлення містить важливу інформацію. Це повідомлення може містити важливу інформацію про Ваше звернення щодо страховального покриття через Premera Blue Cross. Зверніть увагу на ключові дати, які можуть бути вказані у цьому повідомленні. Існує імовірність того, що Вам треба буде здійснити певні кроки у конкретні кінцеві строки для того, щоб зберегти Ваше медичне страхування або отримати фінансову допомогу. У Вас є право на отримання цієї інформації та допомоги безкоштовно на Вашій рідній мові. Дзвоніть за номером телефону 800-722-1471 (TTY: 800-842-5357).

**Tiếng Việt (Vietnamese):**

Thông báo này cung cấp thông tin quan trọng. Thông báo này có thông tin quan trọng về đơn xin tham gia hoặc hợp đồng bảo hiểm của quý vị qua chương trình Premera Blue Cross. Xin xem ngày quan trọng trong thông báo này. Quý vị có thể phải thực hiện theo thông báo đúng trong thời hạn để duy trì bảo hiểm sức khỏe hoặc được trợ giúp thêm về chi phí. Quý vị có quyền được biết thông tin này và được trợ giúp bằng ngôn ngữ của mình miễn phí. Xin gọi số 800-722-1471 (TTY: 800-842-5357).